Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?
OBJECTIVE
Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis. We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia.


METHODS
Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin. Serum hemoglobin, haptoglobin and angiogenesis markers of vascular endothelial growth factor and angiopoetin-2 were investigated before and after therapy.


RESULTS
We observed a significant decrease in haptoglobin levels at the end of the treatment period. Hemoglobin levels also decreased but insignificantly by treatment. In contrast with the literature, serum levels of angiogenesis factors did not change significantly by pegylated interferon and ribavirin therapy. We found no correlation of angiogenesis soluble markers with either hemoglobin or haptoglobin.


CONCLUSIONS
This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation. Future research with larger number of patients is needed to find out modifiable factors that will improve the safety of ribavirin therapy.
Yonem
Ozlem
O
University of Cumhuriyet, Department of Gastroenterology, Sivas, Turkey. ozlemyonem@gmail.com
Arslan
Serab
S
Sokmensuer
Cenk
C
Salmanzade
Selale
S
D000328:Adult; D000368:Aged; D000743:Anemia, Hemolytic / Q000139:chemically induced* / Q000188:drug therapy; D042702:Angiopoietin-2 / Q000097:blood; D000998:Antiviral Agents / Q000009:adverse effects*; D005260:Female; D006242:Haptoglobins / Q000032:analysis; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D012254:Ribavirin / Q000009:adverse effects*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
D042702:Angiopoietin-2; D000998:Antiviral Agents; D006242:Haptoglobins; D042461:Vascular Endothelial Growth Factor A; D012254:Ribavirin